scispace - formally typeset
R

Rong-Zong Liu

Researcher at University of Alberta

Publications -  15
Citations -  865

Rong-Zong Liu is an academic researcher from University of Alberta. The author has contributed to research in topics: Breast cancer & Retinoic acid receptor. The author has an hindex of 11, co-authored 15 publications receiving 686 citations. Previous affiliations of Rong-Zong Liu include Cross Cancer Institute.

Papers
More filters
Journal ArticleDOI

Association of FABP5 Expression With Poor Survival in Triple-Negative Breast Cancer: Implication for Retinoic Acid Therapy

TL;DR: Based on multivariate proportional regression analysis, cytoplasmic FABP5 is a significant and independent prognostic marker of overall survival and recurrence-free survival in breast cancer.
Journal ArticleDOI

A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: transcription in rat retina and testis.

TL;DR: Analysis of adult rat testis reveals a pattern of expression that is different from that of the known testis FABP (FABP9) in the testicular germ cells, suggesting distinct roles for these two genes during mammalian spermatogenesis
Journal ArticleDOI

Fatty acid binding proteins in brain development and disease

TL;DR: A number of transcription factors have been shown to be involved in the developmental regulation of FABP gene expression in the brain, such as Reelin-Dab1/Notch which mediates neuron-glia crosstalk during brain development as discussed by the authors.
Journal ArticleDOI

Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling

TL;DR: Analysis of breast patient tumors revealed that high levels of ALDH1A3 correlated with expression of RA‐inducible genes with retinoic acid response elements (RAREs), poorer patient survival and triple‐negative breast cancers, suggesting a potential link between ALDH 1A3 expression and RA signaling especially in aggressive and/or triple‐ negative breast cancers.
Journal ArticleDOI

Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.

TL;DR: It is shown that concentrations of tamoxifen and its metabolites, which accumulate in tumors of patients, killed both ER α-positive and ERα-negative breast cancer cells, and overcoming tamoxIFen-induced activation of the anti-oxidant response element (ARE) could increase the efficacy of tamxifen in treating breast cancer.